This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Prospective Study of Cellular & Clinical Aspects of Mod-Severe Asthma

  • Research type

    Research Study

  • Full title

    Prospective Study of Cellular and Clinical Aspects of Moderate to Severe Asthma

  • IRAS ID

    254003

  • Contact name

    Andrew Menzies-Gow

  • Contact email

    a.menzies-gow@rbht.nhs.uk

  • Sponsor organisation

    Imperial College London

  • Duration of Study in the UK

    4 years, 11 months, 30 days

  • Research summary

    Asthma is the most common chronic respiratory disease and in many countries prevalence continues to rise. Although currently available medications effectively treat the majority of asthma patients, a substantial proportion of patients exist who remain difficult-to-treat. These patients account for a relatively large proportion of asthma hospitalisation and resource expenditure. Much remains unclear regarding the management of difficult-to-treat patients, or concerning the underlying mechanisms driving this processes.

    The aim of this research study is to prospectively study a group of moderate to severe asthmatics to validate a panel of published biomarkers and to discover novel candidate biomarkers. These biomarkers could potentially allow us to distinguish patient sub-groups or disease severity. As such, this is an enabling study which will provide robust biomarkers (including proteins, RNA and clinical physiological and imaging markers) which can be used in the clinical development of novel therapeutic interventions and will provide further insight into the natural history of asthma and the pathogenesis of acute exacerbations.

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    19/LO/1675

  • Date of REC Opinion

    23 Dec 2019

  • REC opinion

    Further Information Favourable Opinion